Results 131 to 140 of about 18,503 (241)

Site-Directed Mutagenesis of anti-CD11b Nanobody to Optimize Production

A previous work from our lab produced nanobody-drug conjugates using 6x-Histidine affinity chromatography, followed by a sortase-mediated bioconjugation strategy.
Finkelstein, Jonah Evan
core  

Peptide‐directed nanovehicles enabling tumor‐selective ROS amplification and antitumor immunity

VIEW, EarlyView.
Cancer cells are vulnerable to oxidative stress, yet exploit immune tolerance to escape destruction. In contrast, their metabolic profile is markedly altered to support rapid proliferation, accompanied by elevated production of reactive oxygen species (ROS).
Manuela Calin, Galyna Bila, Ileana Manduteanu, Rostyslav Bilyy   +3 more
wiley   +1 more source

Nanobodies as next‐generation targeting platforms: From discovery technologies to translational biomedicine

VIEW, EarlyView.
Nanobodies, derived from the variable domains of camelid heavy‐chain‐only antibodies, have emerged as transformative biomedical tools due to their nanoscale size, exceptional stability, and unique capacity to recognize cryptic epitopes. This review provides a comprehensive overview of the field, outlining the structural and biochemical features of ...
Zhenrui Ye, Xianyang Li, Meixiao Zhan
wiley   +1 more source

Advances in deep‐tissue fluorescence imaging through optical clearing: A review

VIEW, EarlyView.
Optical clearing refers to techniques that are used to improve the optical transparency of biological tissues. Optical clearing enables imaging of deeper lying tissues as well as 3D volumetric imaging of whole organs. This review examines reports on the integration of optical clearing with advanced fluorescence imaging techniques, with particular ...
Alaka Pramod, Sanoop Pavithran M, Valery V. Tuchin, Santhosh Chidangil, C. S. Suchand Sandeep   +4 more
wiley   +1 more source

Combining AI Structure Prediction and Integrative Modeling for Nanobody-Antigen Complexes. [PDF]

J Chem Inf Model
Sánchez-Marín M, Giulini M, Bonvin AMJJ.   +2 more
europepmc   +1 more source

A novel nanobody specific for respiratory surfactant protein A has potential for lung targeting

, 2015
Shan-Mei Wang,1,* Xian He,2,* Nan Li,1,* Feng Yu,3 Yang Hu,1 Liu-Sheng Wang,1 Peng Zhang,4 Yu-Kui Du,1 Shan-Shan Du,1 Zhao-Fang Yin,1 Ya-Ru Wei,1 Xavier Mulet,5 Greg Coia,6 Dong Weng,1 Jian-Hua He,3 Min Wu,7 Hui-Ping Li1 1Department of Respiratory ...
Wu M, Mulet X, Hu Y, He JH, Wang LS, Yu F, Coia G, Wei YR, Li N, Zhang P, Du YK, Weng D, Li HP, Wang SM, He X, Yin ZF, Du SS   +16 more
core  

Strategies for enhancing sensitivity in lateral flow assays

VIEW, EarlyView.
Lateral flow assays (LFAs) are essential for cost‐effective, rapid point‐of‐care diagnostics. However, conventional colourimetric LFAs often lack the sensitivity required for low‐abundance biomarkers. This review evaluates six enhancement strategies: flow modulation, sample preconcentration, advanced reporters, chemical signal amplification, structural
Aylar Eslami Saed, Jacopo Giaretta, Syamak Farajikhah, Fariba Dehghani   +3 more
wiley   +1 more source

Near pan-alphavirus neutralization by an antibody-nanobody bispecific. [PDF]

MAbs
Pletnev S, Gardner CL, Sutton MS, Zhang B, Callahan V, Green C, Morano NC, Bylund T, Dunagan MM, Tsybovsky Y, Goldman ER, Shapiro L, Burke CW, Fox JM, Roederer M, Kwong PD, Zhou T.   +16 more
europepmc   +1 more source

A Simplified Strategy for Nanobody Production and Use Based on Functional GST-Nanobody Fusion Proteins

Nanobodies (VHHs or single-domain antibodies) are powerful affinity reagents, but their routine use is often limited by production constraints and by the lack of a conserved Fc region for secondary detection.
Andrés Rivera-Dictter, Guillermo Valenzuela-Nieto, Pablo Mendoza-Soto, Gonzalo A. Mardones, Agustín A. Burgos, José Munizaga, Tammy P. Pástor   +6 more
core   +1 more source

Systemic Treatment of Psoriasis: Current Evidence on Efficacy and Safety

The Journal of Dermatology, EarlyView.
ABSTRACT Systemic treatments for moderate‐to‐severe plaque psoriasis have been advanced from broad immunosuppressants up to agents more selectively targeting cytokines, cytokine receptors, or intracellular signaling. The current systemic treatments mainly consist of conventional systemic agents, biologics targeting tumor necrosis factor (TNF)‐α ...
Teppei Hagino, Naoko Kanda
wiley   +1 more source